|
| Monday, June 9, 2025 |
|
|
Everest Medicines Presents Positive Results from Phase 1b/2a Clinical Trial of EVER001 for Primary Membranous Nephropathy at ERA 2025 |
| At the 62nd European Renal Association Congress (ERA 2025), Everest Medicines unveiled new clinical data on EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor, in patients with primary membranous nephropathy (pMN). more info >> |
|
|
雲頂新耀EVER001亮相ERA 2025 探索原發性膜性腎病治療新路徑 |
| 在第62屆歐洲腎臟協會年會（ERA 2025）上，雲頂新耀（HKEX：1952.HK）自主研發、擁有全球權益的新一代共價可逆BTK抑制劑EVER001首次以集中口頭報告形式發佈其在原發性膜性腎病（pMN）中的階段性臨床研究數據。 more info >> |
|
|
云顶新耀EVER001亮相ERA 2025 探索原发性膜性肾病治疗新路径 |
| 在第62届欧洲肾脏协会年会（ERA 2025）上，云顶新耀（HKEX：1952.HK）自主研发、拥有全球权益的新一代共价可逆BTK抑制剂EVER001首次以集中口头报告形式发布其在原发性膜性肾病（pMN）中的阶段性临床研究数据。 more info >> |
|
| Wednesday, May 7, 2025 |
|
|
Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China |
| Everest Medicines (HKEX: 1952.HK) today announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA). more info >> |
|
|
雲頂新耀宣佈耐賦康(R)獲得中國國家藥品監督管理局完全批准 全面拓展IgA腎病治療人群 |
| 今日，雲頂新耀（HKEX: 1952.HK）宣佈，其核心產品耐賦康(R)（布地奈德腸溶膠囊，NEFECON(R)）正式獲得中國國家藥品監督管理局（NMPA）完全批准。 more info >> |
|
|
云顶新耀宣布耐赋康(R)获得中国国家药品监督管理局完全批准 全面拓展IgA肾病治疗人群 |
| 今日，云顶新耀（HKEX: 1952.HK）宣布，其核心产品耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）正式获得中国国家药品监督管理局（NMPA）完全批准。 more info >> |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
|
雲頂新耀「摘B」成功 盈利能力與創新價值獲雙重驗證 |
| 今日，雲頂新耀（HKEX 1952.HK）宣佈公司已獲香港聯交所批准，將「B」標記從股票代碼中移除 more info >> |
|
|
云顶新耀"摘B"成功 盈利能力与创新价值获双重验证 |
| 今日，云顶新耀（HKEX 1952.HK）宣布公司已获香港联交所批准，将"B"标记从股票代码中移除。 more info >> |
|
| Wednesday, March 19, 2025 |
|
|
雲頂新耀啟動嘉善工廠伊曲莫德生產建設項目 加速本地化供應佈局 |
| 今日，雲頂新耀宣佈正式啟動伊曲莫德（VELSIPITY(R)）位於嘉善工廠的生產建設項目，以支持該藥物的本地化生產，進一步滿足中國及亞洲市場對潰瘍性結腸炎（UC）治療的需求。該項目總投資達7000萬元，預計投產後年產能可達5000萬片，供應範圍涵蓋中國大陸、中國香港、中國澳門、中國台灣、韓國及新加坡等市場。 more info >> |
|
|
|
|
